Skip to content
FORSIDEN
Log ind Opret konto
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Juli 2022

Genmab — Juli 2022

Planlagt Fastgjort Låst Flyttet Genmab
808 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • E Offline
    E Offline
    E_L
    wrote on sidst redigeret af
    #779

    Genmab is co-promoting Tivdak in the U.S. and will lead
    commercial operational activities in Japan. Seagen is leading commercial operational activities in the
    U.S. and will lead commercial operational activities in Europe and China. In these four markets there will
    be a 50:50 cost and profit split. In any other markets, Seagen will commercialize Tivdak and Genmab will
    receive royalties based on a percentage of aggregate net sales ranging from the mid-teens to the midtwenties. T

    1 Reply Last reply
    0
    • E Offline
      E Offline
      E_L
      wrote on sidst redigeret af
      #780

      so far we are only on the US

      1 Reply Last reply
      0
      • E Offline
        E Offline
        E_L
        wrote on sidst redigeret af
        #781

        *in

        1 Reply Last reply
        0
        • D Offline
          D Offline
          deleted-user
          wrote on sidst redigeret af
          #782

          Fra aftalen 2017 "Each party has the option to co-promote by employing up to 40 percent of the sales effort in the other party's territories."

          1 Reply Last reply
          0
          • SolsenS Offline
            SolsenS Offline
            Solsen
            wrote on sidst redigeret af
            #783

            Det ligner at Genmab kun booker salget i Japan. Fik ikke læst det hele i første omgang - beklager. Genmab har sagt at Seagan skal træne deres salgsfolk i US.

            1 Reply Last reply
            0
            • B Offline
              B Offline
              bikube
              wrote on sidst redigeret af
              #784

              Over halvdelen af dagens hidtidige omsætning skete kl. 10,23, med en stigning fra 2630 til 2639, det var da noget af et hug.

              1 Reply Last reply
              0
              • BulderB Offline
                BulderB Offline
                Bulder
                wrote on sidst redigeret af
                #785

                Er det ikke uden betydning hvem der booker hvad. De deler jo i porten alligevel.

                1 Reply Last reply
                0
                • SolsenS Offline
                  SolsenS Offline
                  Solsen
                  wrote on sidst redigeret af
                  #786

                  Jo men det var jo en del af diskussionen, hvornpr Genmab indtægtsførte salget.

                  1 Reply Last reply
                  0
                  • SolsenS Offline
                    SolsenS Offline
                    Solsen
                    wrote on sidst redigeret af
                    #787

                    Tror der lidt prestige i at få lov at booke salget.

                    1 Reply Last reply
                    0
                    • SolsenS Offline
                      SolsenS Offline
                      Solsen
                      wrote on sidst redigeret af
                      #788

                      Lidt travl ved tasterne så der skal gættes lidt - sorry.

                      1 Reply Last reply
                      0
                      • SolsenS Offline
                        SolsenS Offline
                        Solsen
                        wrote on sidst redigeret af
                        #789

                        Må hellere nyde solen i stedet.

                        1 Reply Last reply
                        0
                        • P Offline
                          P Offline
                          ProinvestorNEWS
                          wrote on sidst redigeret af
                          #790

                          Aktier/middag: Rockwool og Vestas bidrager på grøn dag
                          https://www.proinvestor.com/investornyt/857874/aktier-middag-rockwool-og-vestas-bidrager-pa-gron-dag

                          1 Reply Last reply
                          0
                          • D Offline
                            D Offline
                            deleted-user
                            wrote on sidst redigeret af
                            #791

                            Enig Solsen. Tænker også der er prestige i principal-titlen og det, at bogføre nettoomsætning i stedet for netto profit, øger trods alt toplinjen mest. Så er det naturligvis også interessant, at følge investeringen i salgsapparatet og de mange personer der er nyansat. Det skal skabe afkast præcis som investeringer i RD. Jeg kalder det monitorering af Jan 🙂

                            1 Reply Last reply
                            0
                            • D Offline
                              D Offline
                              deleted-user
                              wrote on sidst redigeret af
                              #792

                              I øvrigt - en detalje. Af 2017 aftalen fremgår der 50:50 split af "costs and profits". Bliver det ikke umuliggjort, når man indblander faste royaltysatser i visse områder.... Spøjst

                              1 Reply Last reply
                              0
                              • E Offline
                                E Offline
                                E_L
                                wrote on sidst redigeret af
                                #793

                                Seagen earnings call transcript https://www.fool.com/earnings/call-transcripts/2022/07/29/seagen-inc-sgen-q2-2022-earnings-call-transcript/

                                1 Reply Last reply
                                0
                                • BulderB Offline
                                  BulderB Offline
                                  Bulder
                                  wrote on sidst redigeret af
                                  #794

                                  50:50 split er i de 4 markeder Japan, Kina Europa og US. alle andre markeder er der royalties til Genmab.

                                  1 Reply Last reply
                                  0
                                  • D Offline
                                    D Offline
                                    deleted-user
                                    wrote on sidst redigeret af
                                    #795

                                    og her har jeg gået og troet det skulle være en 50/50 aftale. Bemærker endvidere, at Genmab bogfører "sales" i Japan. Det må være direkte på toplinjen som det eneste sted

                                    1 Reply Last reply
                                    0
                                    • nohopeN Offline
                                      nohopeN Offline
                                      nohope
                                      wrote on sidst redigeret af
                                      #796

                                      Den aftale lyder da som noget rod.

                                      1 Reply Last reply
                                      0
                                      • D Offline
                                        D Offline
                                        deleted-user
                                        wrote on sidst redigeret af
                                        #797

                                        Rod? Måske. Men nu er det ikke en citronmåne der skal deles 🙂

                                        1 Reply Last reply
                                        0
                                        • E Offline
                                          E Offline
                                          E_L
                                          wrote on sidst redigeret af
                                          #798

                                          Distribution and efficacy of ofatumumab and ocrelizumab in humanized CD20 mice following subcutaneous or intravenous administration https://www.frontiersin.org/articles/10.3389/fimmu.2022.814064/full?utm_source=S-TWT&utm_medium=SNET&utm_campaign=ECO_FIMMU_XXXXXXXX_auto-dlvrit

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper